Related references
Note: Only part of the references are listed.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
SAT-277-Screening diabetic patients at risk for complications of nonalcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations
Valentin Blank et al.
JOURNAL OF HEPATOLOGY (2019)
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
Ankur Srivastava et al.
JOURNAL OF HEPATOLOGY (2019)
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M. Anstee et al.
HEPATOLOGY (2019)
Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Real-Life Populations
Jerome Boursier et al.
HEPATOLOGY (2019)
Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany
Jan Kramer et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement
T. Karlas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes
A. L. Sberna et al.
DIABETIC MEDICINE (2018)
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society
David Petroff et al.
DIGESTIVE AND LIVER DISEASE (2018)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Zobair M. Younossi et al.
HEPATOLOGY (2018)
Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis
Preya J. Patel et al.
INTERNAL MEDICINE JOURNAL (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
Zobair M. Younossi
LIVER TRANSPLANTATION (2018)
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany
Christian Labenz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
Thomas Karlas et al.
JOURNAL OF HEPATOLOGY (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Treatment of NAFLD with diet, physical activity and exercise
Manuel Romero-Gómez et al.
JOURNAL OF HEPATOLOGY (2017)
Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD
S. Petta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
S2k Guideline non-alcoholic fatty liver disease AWMF Register Nr. 021-025 Version January 2015, first edition
E. Roeb et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2015)
A population-based study on the prevalence of NASH using scores validated against liver histology
Jenni Hyysalo et al.
JOURNAL OF HEPATOLOGY (2014)
Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy
Thomas Karlas et al.
PLOS ONE (2014)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Share Paper
